UBS Maintains Buy on AdaptHealth, Lowers Price Target to $10
UBS analyst Kevin Caliendo maintains AdaptHealth (NASDAQ:AHCO) with a Buy and lowers the price target from $14 to $10.
Read original at benzingaStocks · News reference
AdaptHealth Q2 EPS $(0.99) Misses $0.18 Estimate, Sales $740.300M Miss $848.627M Estimate
AdaptHealth (NASDAQ:AHCO) reported quarterly losses of $(0.99) per share which missed the analyst consensus estimate of $0.18 by 650 percent. This is a 1090 percent decrease over earnings of $0.10 per share from the
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 4, 2026, 11:02 AM
- Checked
- Aug 4, 2026, 11:02 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
RBC Capital Maintains Outperform on AdaptHealth, Lowers Price Target to $8
RBC Capital analyst Ben Hendrix maintains AdaptHealth (NASDAQ:AHCO) with a Outperform and lowers the price target from $15 to $8.
Read original at benzingaTruist Securities Maintains Buy on AdaptHealth, Lowers Price Target to $9
Truist Securities analyst David Macdonald maintains AdaptHealth (NASDAQ:AHCO) with a Buy and lowers the price target from $14 to $9.
Read original at benzingaCrude Oil Down Over 5%; McDonald's Earnings Top Views
U.S. stocks gain with Nasdaq up more than 2% on Tuesday. Dow up 1.79% to 54,129.35, Nasdaq up 2.22% to 26,490.24, S&P 500 up 1.64% to 7,725.48. Tech shares jump 3.8%, utilities down 0.5%. McDonald's beats earnings estimates. Ibotta, Backblaze, Corvex up, Adapthealth, Better Home & Finance, Clearpoint Neuro down.
Read original at benzinga